Newswire (Published: Tuesday, December 12, 2017, Received: Thursday, December 7, 2017, 11:24:05 AM CST)

Word Count: 552

Data on Prostate Cancer Described by Researchers at Mayo Clinic (Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion)

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting from Rochester, Minnesota, by NewsRx journalists, research stated, "To reduce unnecessary prostate biopsies while using novel tests judiciously, we created a tool to predict the probability of clinically significant prostate cancer (CSPC) vs. low-risk prostate cancer or negative biopsy (i.e., when intervention is likely not needed) among men undergoing initial or repeat biopsy. Separate models were created for men undergoing initial and repeat biopsy, identified from our institutional biopsy database and the placebo arm of the REDUCE trial, respectively, to predict the presence of CSPC (Gleason >= 7 or >33% of cores involved)."

The news correspondents obtained a quote from the research from Mayo Clinic, "Predictors considered included age, race, body mass index, family history of prostate cancer, digital rectal examination, prostate volume, prostate-specific antigen (PSA), free-to-total PSA, presence of high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation on prior biopsy, number of prior biopsies, and number of cores previously taken. Multivariable logistic regression models that minimized the Akaike Information Criterion and maximized out-of-sample area under the receiver operating characteristics curve (AUC) were selected. Of 7,963 biopsies (initial = 2,042; repeat = 5,921), 1,138 had CSPC (initial = 870 [42.6%]; repeat = 268 [4.5%]). Age, race, body mass index, family history, digital rectal examination, and PSA were included in the initial biopsy model (out-of-sample AUC = 0.74). Age, prostate volume, PSA, free-to-total PSA, prior high-grade prostatic intraepithelial neoplasia, and number of prior biopsies were included in the repeat biopsy model (out-of-sample AUC = 0.81). These prediction models may help guide clinicians in avoiding unnecessary initial and repeat biopsies in men unlikely to harbor CSPC."

According to the news reporters, the research concluded: "This tool may also allow for the more judicious use of novel tests only in patients in need of further risk stratification before deciding whether to biopsy."

For more information on this research see: Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. Urologic Oncology-Seminars and Original Investigations, 2017;35(10):88-95. Urologic Oncology-Seminars and Original Investigations can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting B. Bhindi, Mayo Clinic, Dept. of Urol, Rochester, MN 55902, United States. Additional authors for this research include H.Y. Jiang, C. Poyet, T. Hermanns, R.J. Hamilton, K. Li, A. Toi, A. Finelli, A.R. Zlotta, T.H. van der Kwast, A. Evans, N.E. Fleshner and G.S. Kulkarni.

Keywords for this news article include: Rochester, Minnesota, United States, North and Central America, Diagnostics and Screening, Prostate-Specific Antigen, Enzymes and Coenzymes, Prostatic Neoplasms, Prostate Cancer, Oncology, Mayo Clinic.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Mayo Clinic


Central America
North America
United States
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer